INAB · In8bio, Inc. · Executive Compensation
$1.00
+0.04 (+4.17%)
At close · Oct 28
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's business strategy, its existing cash of $18.0 million as of June 30, 2026 is not anticipated to fund the Company's projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company's ability to continue to operate as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$9.46M
Shares
9.86M
Volume · Oct 28
13.12K
Avg daily vol (3M)
54.52K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| William Ho | Chief Executive Officer | $953,720 |
| Kate Rochlin | President and Chief Operating Officer | $688,850 |
| Patrick McCall | Chief Financial Officer | $677,196 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| William Ho | President and Chief Executive Officer | $1,453,512 |
| Kate Rochlin | Chief Operating Officer | $790,083 |
| Patrick McCall | Chief Financial Officer | $780,377 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| William Ho | President and Chief Executive Officer | $1,854,166 |
| Trishna Goswami | Chief Medical Officer | $1,065,676 |
| Patrick McCall | Chief Financial Officer | $914,843 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| William Ho | President and Chief Executive Officer | $1,729,646 |
| Trishna Goswami | Chief Medical Officer | $999,307 |
| Kate Rochlin | Chief Operating Officer | $934,681 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| William Ho | President and Chief Executive Officer | $2,291,689 |
| Patrick McCall | Chief Financial Officer | $1,520,333 |
| Lawrence Lamb | Executive Vice President, Chief Scientific Officer | $918,754 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lawrence Lamb | Executive Vice President, Chief Scientific Officer | $1,676,810 |
| William Ho | President and Chief Executive Officer | $1,447,707 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Corinne Epperly | Class II director | Appointed | 2026-05-07 |
| Peter Brandt | Class II director | Appointed | 2026-05-07 |
| Jeremy Graff | Interim Chair of the Board | Appointed | 2026-02-27 |
| Alan S. Roemer | director of the Board | Resigned | 2026-02-27 |
| Kate Rochlin | President | Appointed | 2026-02-09 |
| Travis Whitfill | Board and its committees | Resigned | 2025-03-05 |
| Corinne Epperly, M.D. | Class II director | Appointed | 2023-12-07 |
| Jeremy Graff, Ph.D. | Class I director | Appointed | 2023-05-01 |
Leadership
- William Ho CEO, Board Member
- Jeremy Graff Chairman, Board Member
- Patrick McCall CFO
- Kate Rochlin COO
- Kate Rochlin, Ph.D. COO
- Corinne Epperly Board Member
- Corinne Epperly, M.D. Board Member
- Emily Fairbairn Board Member
- Jeremy Graff, Ph.D. Board Member
- Luba Greenwood Board Member
- Peter Brandt Board Member